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Abstract. Malaria transmission from humans to mosquitoes is modulated by human host immune factors. Under-
standing mechanisms by which the human host response may impair parasite infectivity for mosquitoes has direct
implications for the development of transmission-blocking vaccines. We hypothesized that despite a low transmission
intensity of malaria in the Peruvian Amazon region of Iquitos, transmission-blocking immunity against Plasmodium
vivax might be common, given an unexpectedly high proportion of asymptomatic parasitemic individuals in this region.
To test this hypothesis, the ability of symptomatic P. vivax malaria patients to experimentally infect wild-caught outbred
Anopheles darlingi mosquitoes was tested using the indirect membrane feeding technique. Only half (52/102) of P. vivax
parasitemic patients successfully infected mosquitoes. Transmitters were more likely to have gametocytes (OR 6.35,
P  0.003), high parasitemia (OR 3.79, P  0.024), and, in terms of basic clinical parameters, a slower pulse rate (mean
± SD: 82.3 ± 12.3 versus 88.7 ± 13.5, P  0.016) than non-transmitters. Log10 gametocytemia and log10 real-time reverse
transcriptase Pvs25 PCR quantifying gametocytes were significantly and positively correlated with oocyst counts (cor-
relation coefficient 0.505, R2  0.26, P  0.001). These experiments are the first to establish a system of determining
transmission patterns in experimental infection of outbred natural neotropical malaria vectors in the Amazon region.
Patients with P. vivax inefficiently infect outbred An. darlingi mosquitoes, raising the possibility that some degree of
naturally occurring transmission-blocking immunity is present on a population basis in the Peruvian Amazon, an area
of low intensity of malaria transmission.
INTRODUCTION
Malaria transmission begins with uptake of viable, mature
gametocytes by female Anopheles mosquitoes during inges-
tion of an infectious blood meal. Patients harboring malaria
parasites are not equally infectious to mosquitoes. Naturally
occurring transmission-blocking and transmission-enhancing
activity (both immune and non-immune mediated) present in
serum has been demonstrated both for Plasmodium falci-
parum and Plasmodium vivax in endemic regions. Nonethe-
less, molecular targets of P. vivax transmission-blocking im-
munity have not been delineated in the field setting.1–3
Infectivity of Plasmodium gametocytes for mosquitoes has
been shown to be modulated by antibody,4 complement,5 and
leukocytes.6 This combination of factors leads to variability in
the ability of gametocytemic individuals to infect mosquitoes.
Intuitively, the three major determinants would be parasite
infectivity, vector competence, and host factors (genetic, im-
mune, and non-immune). Quantity of gametocytes as deter-
mined by light microscopy has not been demonstrated to pre-
dict P. vivax transmission to mosquitoes.7
P. vivax is more common than P. falciparum as a cause of
malaria in many parts of the tropics and subtropics outside of
sub-Saharan Africa.8 Malaria caused by P. vivax occurs in
many regions of Asia and Latin America but has been un-
derstudied and underappreciated as a public health threat
there.8 In Peru, the incidence of malaria has increased dra-
matically since the early 1990s.9 P. vivax remains the pre-
dominant cause of malaria in the region and is a considerable
source of morbidity to people of all ages, especially during
pregnancy where it is associated with maternal anemia and
low birthweight.10
The principal malaria vector in the Amazon basin is
Anopheles darlingi, an aggressive, anthropophilic mosquito
that has invaded the western Amazon over the past 15 years
due, at least in part, to deforestation,11 and has led to epi-
demic malaria in the region.12 Despite being outnumbered
by another malaria-competent anopheline mosquito, Anophe-
les benarrochi (71% vs. 24%), An. darlingi has been found to
have a much higher infection rate (1% vs. 0.14%), which,
combined with being highly anthropophilic, has led to its be-
ing the most important malaria vector in the Amazon ba-
sin.13,14 However, because An. darlingi cannot be propagated
in colonies, the natural P. vivax–An. darlingi combination has
been difficult to study under experimental settings using in-
fected humans as sources of infectious blood meals to deter-
mine the biologic parameters of transmission. To do so re-
quires a logistically challenging system in which An. darlingi is
caught in the field, induced to lay eggs to obtain uninfected F1
mosquitoes, and infected with blood from a naturally infected
human in the laboratory setting. Only in this experimental
setting can naturally acquired immunity that closely mimics
the field setting be simulated.
In areas of high malaria transmission, patients develop
clinical immunity as a result of an immune response that con-
trols, but does not eliminate, parasitemia while simulta-
neously avoiding severe pathology. This phenomenon is well
described for P. falciparum15 and more recently for P.
vivax16–18 malaria. Interestingly, in the Peruvian Amazon, a
site of low malaria transmission intensity, we and others have
demonstrated an unexpectedly high prevalence of asymptom-
atic malaria with one-third of slide-positive and three-fourths
of PCR-positive patients being asymptomatic.19,20 These pa-
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tients serve as a reservoir of infection, but the transmission
pattern in this group is unknown.
This study was conducted to determine the ability of P.
vivax-infected patients in the Peruvian Amazon to infect An.
darlingi mosquitoes. We hypothesized that, despite low ende-
micity, transmission-blocking immunity develops against P.
vivax in the Peruvian Amazon. Using the natural outbred An.
darlingi–P. vivax pairing, we also determined the relationship
between P. vivax parasitemia, gametocytemia as determined
by light microscopy and quantitative reverse transcriptase
PCR, and clinical features and infectivity for An. darlingi
mosquitoes.
MATERIALS AND METHODS
Study site. Patient enrollment and experimental mosquito
infections were carried out in Iquitos, the capital city of the
department of Loreto, Peru, over a period of 14 months from
May 2004 to June 2005. Enrollment criteria were patients with
acute fever and P. vivax parasitemia. The region comprises
nearly one-fourth of the landmass of Peru and has the eco-
logical characteristics of the Amazon lowlands. Malaria cases
occur nearly throughout the year, with seasonal peaks from
January to September. P. vivax prevalence in this population
is 5 times more than that of P. falciparum (14% vs. 3%) as has
been shown by active surveillance.19
Patient recruitment method and data collection. This study
was approved by the Institutional Review Boards/Ethical
Committees of the University of California San Diego, Uni-
versidad Peruana Cayetano Heredia, A.B. Prisma, and
United States Department of Defense. Permission to carry
out the study was provided by the Loreto Director of Health,
Iquitos, Peru. Informed consent was obtained from all par-
ticipants prior to enrollment. All participation was voluntary,
and subjects could opt out at any time during the study. All
parasitemic patients, regardless of decision to participate,
were offered free anti-malarial chemotherapy according to
Peruvian Ministry of Health guidelines. Patients were sought
from the outpatient department of Hospital Apoyo Iquitos
and the health posts at the villages of Varillal and Santo To-
mas. No patient had been on anti-malarial therapy on entry to
the study. Febrile patients (defined as having an oral tem-
perature > 37.7°C) routinely have blood smears made when
presenting for care. Samples were prepared for thick and thin
smear microscopy using 5% Giemsa stain, and the slides were
examined on site by an experienced Ministry of Health mi-
croscopist. This diagnosis was considered standard for inclu-
sion of patients in the study. Patients were excluded if they
had severe or complicated malaria as defined by the World
Health Organization, serious co-morbid conditions (e.g.,
HIV/AIDS or malnutrition; none were excluded for these
reasons), or were pregnant (2 were excluded). Symptomatic
P. vivax patients 18 years and older were invited to participate
in the study, and informed consent was obtained from those
willing. Data regarding age, sex, occupation, place of resi-
dence, and history of travel were obtained. Physical exami-
nation was done and included general appearance, heart rate,
respiratory rate, pallor, icterus, and splenomegaly. Informa-
tion regarding past history of malaria (type, frequency), date
of onset of current symptoms, and use of drugs (anti-malarials
and anti-pyretics) was noted.
Mosquitoes. An. darlingi mosquitoes were caught at night
using human bait in the study villages under U.S. Department
of Defense-approved protocols, including strict attention to
occupational safety, provision of malaria prophylaxis, and
surveillance for malaria as the cause of febrile illness. Adult
female An. darlingi mosquitoes were brought to the Iquitos
insectary and fed on chicken blood to induce egg-laying, and
F1 mosquitoes were then reared to adults using established
methods.21 Mosquitoes were fed on parasite-containing blood
3–4 days post-emergence.
Membrane-feeding assays. A member of the study team
accompanied the patients to the insectary, and a physician
was present throughout the procedure. Blood samples were
obtained in heparinized tubes, maintained at 37°C, and blood
smears repeated. Two and a half milliliters of blood was
added to a 5-cm diameter hand-blown glass feeder (Perpetual
Systems Corp., Rockville, MD) closed with Parafilm (Ameri-
can National Can, Chicago, IL). To prevent exflagellation of
microgametocytes, a constant temperature of 37°C was main-
tained using a water-jacketed circulation system.22 The mos-
quitoes (25 per carton) were allowed to feed for 15 min in the
dark, after which time the glass membrane feeder was re-
moved from the top of the carton and unengorged mosquitoes
were removed. Blood samples from each patient were fed to
mosquitoes in 3 separate cartons simultaneously. After feed-
ing, all mosquitoes were kept in the insectary (22–27°C and
70–80% humidity) and provided with 20% sucrose daily until
they were dissected on days 7, 8, and 9 after feeding. Midguts
were dissected in a drop of phosphate-buffered saline, and
oocysts counted by examination under 10× light microscopy.
Immediately after blood draw, patients were given anti-
malarial drugs (chloroquine and primaquine) per Peruvian
Ministry of Health guidelines. A second blood smear was
prepared at the time of blood draw to confirm the diagnosis
and to quantify parasitemia and gametocytemia. The follow-
ing system was used: < 1+, at least 1 parasite/100 high-power
field (HPF); 1+, 1 parasite/HPF; 2+, 2–20 parasites/HPF; 3+,
21–200 parasites/HPF; 4+, > 200 parasites/HPF.
Real-time reverse transcriptase PCR. A real-time reverse
transcriptase PCR based on the Pvs25 gene (GenBank acces-
sion no. AB033343) was developed as an alternative method
for quantifying P. vivax gametocytemia.23 Primers (forward,
5-AACGAAGGGCTGGTGCACCTTT-3, 5-AGCA-
ACCTGCACTTTGGATTTCCG-3) were designed to am-
plify Pvs25. The predicted fragment size of 267 bp was am-
plified from total genomic DNA obtained from whole blood
containing P. vivax from a patient. The amplified product was
cloned into the pCR 2.1-TOPO plasmid vector. A tenfold
dilution of the plasmid DNA starting with 1010 plasmid cop-
ies/L (as determined by spectrophotometry at OD280) was
used as a positive control and for making a standard curve.
RNA isolation from freshly obtained infected blood from
Peru was done using the PAXgene Blood RNA Kit (Qiagen
Inc., Valencia, CA). Briefly, 2.5 mL of whole blood was col-
lected in PAXgene Blood RNA Tubes (Becton Dickinson
(BD), Franklin Lakes, NJ, catalog no. 76216) and stored at
− 20°C after being allowed to incubate at room temperature
for 2 hours. All samples were processed within 2 weeks of
collection using the PAXgene Blood RNA Kit. TaqMan
probes were designed for the Pvs25 real-time PCR assays. A
5 6-FAM reporter dye was selected, with a 3 Black Hole
Quencher on the end. Probe concentration was optimized at
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a final concentration of 0.1 M in each reaction, primer final
concentration was 0.2 M, and 10 L of RNA template from
each extraction was used for each reverse transcriptase PCR
reaction. The reverse transcriptase PCR cycles were as fol-
lows: 50°C × 15 minutes, 95°C × 2 minutes, 94°C × 10 seconds,
55°C × 45 seconds, plate read, 45 cycles total. For each reverse
transcriptase PCR run, RNA samples were run alongside ten-
fold dilutions of the plasmid DNA that were performed in
triplicate to generate a reliable standard curve. For each
RNA sample subjected to reverse transcriptase PCR (using
Invitrogen’s one-step reverse transcriptase PCR reagents with
reverse transcriptase and Taq polymerase), a reverse tran-
scriptase minus control was run using the standard PCR re-
agents with Taq polymerase only for contaminating genomic
DNA. The real-time probe used was the 5 6-FAM-
AACCCAGACCCAGCACAGGTAAACATG-3 Black
Hole Quencher.
Statistical analysis. For analysis purposes, a person was de-
fined as a “transmitter” if a blood sample from that person
had successfully infected at least one mosquito. Univariate
analyses, using the 2 test or t test to compare means where
appropriate, were used to examine which variables were as-
sociated with transmission of infection to mosquitoes. A t test
was also used to compare the mean percentage of mosquitoes
infected by parasitemia group, and the Mann-Whitney U test
was used to compare the number of oocysts per infected mid-
gut with parasitemia group. Relationships between real-time
reverse transcriptase PCR quantification of gametocytes, ga-
metocytemia, oocysts per infected midgut, and percentage of
mosquitoes infected were compared using simple linear re-
gression. Two-sided P values < 0.05 were considered statisti-
cally significant. Data were analyzed using the SPSS 12.0
(SPSS, Inc., Chicago, IL) statistical package.
RESULTS
Patient data. A total of 102 patients with symptomatic P.
vivax infection were enrolled in the study (Table 1). The sex
ratio was approximately 2:1 with 65 (64%) men and 37 (36%)
women. The mean age was 34 ± 12 SD years (range 18–63
years). All had at least one of the following clinical symptoms
by history: fever, chills, or headache (except for 1 patient for
whom data were missing). Most patients (80%) had all 3
symptoms on presentation and were seen within 7 days from
onset of illness. Sixty percent (60/102) of the patients gave
history of prior malaria episodes. About two-thirds (69/102)
of patients admitted to taking an analgesic, anti-pyretic, or
anti-inflammatory medicine (acetaminophen, ibuprofen,
naproxen, or aspirin) some time during the course of their
illness. At the time of membrane feeding, half (51/102) of the
patients were febrile, with a temperature of 37.5°C or more
(range 37.7–40.1°C). Pulse rate ranged from 60 to 120 beats
per minute with a mean of 85.4 ± 13.2 SD. Pallor was noted in
65% (66/102) of patients, but because the measurements were
not standardized, this variable was not included in the analysis.
Results of light microscopy quantification of P. vivax par-
asitemia. Diagnoses of all patients reported as having P. vivax
malaria by Ministry of Health microscopists at all study sites
were confirmed independently in our laboratory. The smear
results ranged from < 1 + to 3 +, with a majority of them
falling in the 2 + group (77/102). Gametocytemia ranged from
0 to 106 gametocytes per 100 HPF with a mean of 20.61.
Infectivity of P. vivax patients for An. darlingi mosquitoes.
A total of 4,017 mosquitoes successfully fed on infected blood
using the artificial membrane feeding technique, with 2,631
(65%) surviving until the time of midgut dissection. Approxi-
mately 50% (52/102) of the patients specimens infected mos-
quitoes, and 23% (602/2,631) of mosquitoes had at least one
reported oocyst. The mean oocyst load per infected midgut
was 11.5 ± 25.9 with a range of 1–175.
Relationship of P. vivax parasitemia and gametocytemia to
transmission of infection to mosquitoes. In P. vivax transmit-
ters, the frequency of high parasitemia (2 + or 3 +) was higher
than in non-transmitters (92% vs. 76%). The odds of P. vivax
transmission to mosquitoes for those with high (2 + or 3 +)
versus low parasitemia (< 1 + or 1 +) were statistically sig-
nificantly greater (Odds Ratio 3.79, 95% CI: 1.13–12.7, P 
0.024). The higher parasitemia groups also had a greater
mean percentage of mosquitoes infected (Figure 1a, P 
0.001 by t test) and a borderline statistically significant greater
number of oocysts per infected midgut (Figure 1b, P  0.09
by Mann-Whitney U test). After grouping the cases into those
with or without gametocytes on smear examination, the odds
of P. vivax transmission for those with gametocytes versus no
gametocytes were significantly higher (OR 6.35, 95% CI:
1.70–23.8, P  0.003).
Results of real-time reverse transcriptase PCR. Real-time
PCR data were available for 37 patients; linear regression
showed a significant and positive correlation between log10
gametocytemia and log10 real-time reverse transcriptase PCR
results (R2  0.26, P  0.001; Figure 2); Log10 gameto-
cytemia and the percentage of mosquitoes infected (R2 
0.23, P < 0.001; Figure 3); and log10 gametocytemia and log10
TABLE 1
Comparison of clinical aspects of patients who transmitted vs. those








(n  50) P value
Sex
% male 64 64 0.96
Age (years)
< 25 31 35 0.35
25–34 31 18
 35 + 39 47
Mean ± SD 32.6 ± 10.9 34.8 ± 13.6 0.37
Past malaria episodes (a)
Had malaria in past 67 66 0.94
Chills
Present 96 96 0.97
Headache
Present 100 98 0.31
Fever
 37.5°C 44 56 0.24
 40.0°C 6 12 0.31
Fever medications
Recent history of use 73 72 0.90
Pulse (b)
Mean ± SD 82.3 ± 12.3 88.7 ± 13.5 0.016
Parasitemia (categories)
Groups 1–2 8 24 0.024
Groups 3–4 92 76
Gametocytemia by smear
(categories)
0 vs. any (> 0) 94 72 0.003
* Boldface indicates statistically significant association.
(a) n  101 for past malaria episodes; (b) n  98 for pulse.
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oocysts/midgut (R2  0.26, P  0.001; Figure 4). The corre-
lation between log10 real-time reverse transcriptase PCR and
log10 oocysts/midgut was not statistically significant, but that
between log10 real-time reverse transcriptase PCR and per-
centage of mosquitoes infected was statistically significant
(R2  0.21, P  0.004; Figure 5). Univariate analysis of pulse
using Student’s t test to compare means shows that transmit-
ters had a lower mean pulse than non-transmitters (mean ±
standard deviation: 82.3 ± 12.3 vs. 88.7 ± 13.5, respectively;
P  0.016). There was no clear relationship between fever
( 37.5°C) at time of membrane feed and transmission (44% vs.
56% for transmitters versus non-transmitters, respectively).
DISCUSSION
Four major findings emerged from this study. First, we suc-
cessfully infected an outbred group of An. darlingi mosqui-
toes with P. vivax obtained ex vivo from malaria patients.
Second, there was incomplete and inefficient transmission of
infection from patients (half of P. vivax parasitemic patients)
to outbred An. darlingi mosquitoes in an area with low ma-
laria endemicity. Third, P. vivax transmitters were more likely
to have gametocytes on smear, high parasitemia, and a lower
mean pulse than non-transmitters. Fourth, there was a corre-
lation between smear and real-time reverse transcriptase
PCR gametocytemia.
Our findings are in agreement with other published data
where symptomatic P. vivax patients were studied. In studies
where mosquitoes were allowed to feed directly on symptom-
atic Thai P. vivax patients, there was successful transmission
of infection from 63% to 73% cases with a mean oocyst load
of 9–13.4 and a mean frequency of infection of 43–57% of
mosquitoes fed.7,24 Similarly, membrane feeds using blood
from P. vivax-infected symptomatic Thai patients resulted in
FIGURE 2. Association of log10 P. vivax gametocytemia (exclud-
ing null values) and log10 real-time reverse transcriptase PCR quan-
tification of Pvs25 mRNA; R2  0.26, P  0.001, N  37.
FIGURE 3. Association of log10 gametocytemia and percent of An.
darlingi mosquitoes infected by membrane feeding assay with ex-
vivo, human-derived P. vivax; R2  0.23, P < 0.001, N  98.
FIGURE 1. Relationship between P. vivax parasitemia and (a) percent of An. darlingi mosquitoes infected (P  0.001 by t test) or (b) oocyst
density in infected midguts (P  0.09 by Mann-Whitney U test). Groups < 1 + and 1 + vs. 2 + and 3 + include patients with < 2 and  2 parasites
per HPF, respectively, on peripheral blood smears. Error bars indicate standard error of mean.
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a mean oocyst load of 8.8 with 50.3% mosquitoes infected.24
One important difference in these studies was that the mos-
quitoes used were Anopheles dirus; these have been raised in
colonies for over 25 years and are genetically inbred. Our
study confirms a previous, smaller study in which wild-caught
An. darlingi mosquitoes were infected in the Brazilian Ama-
zon.25 We, too, demonstrate that experimental infection of a
non-colonizable Anopheles spp. mosquito is feasible. The
present study, however, provides a basis for applying such a
system to assess mechanisms of transmission-blocking immu-
nity in the endemic field setting.
Naturally occurring transmission-blocking immunity has
been demonstrated both for P. falciparum and P. vivax but is
incompletely present in human populations in endemic re-
gions.1–3 The presence of symptomatic or asymptomatic ma-
laria can be used as an indicator of host immunity. Asymp-
tomatic patients, through repeated infections, are more likely
to have transmission-blocking antibodies like those against
Pvs25 and Pvs28 that have been shown to reduce infectivity to
mosquitoes.26 Indeed, asymptomatic P. vivax-infected indi-
viduals are less efficient transmitters, with only 13.5% pa-
tients infecting 0.45% of the mosquitoes with an average of
1.44 oocysts (± 0.18).27 Similar results were reported by Alves
et al., where the infection rate in mosquitoes was 1.2% for
asymptomatic carriers versus 22% for symptomatic pa-
tients.25 In symptomatic patients, other serum factors may
modify the ability of P. vivax gametocytes to infect mosqui-
toes, as seen by enhanced mosquito infection rates after re-
placement of patient plasma with P. vivax-naïve sera or
plasma.24 Future studies will compare mosquito infectivity of
asymptomatic patients to that of symptomatic patients in as-
sociation with determination of transmission-blocking anti-
bodies and pro-inflammatory mediators.
It is possible that different genetic types of P. vivax could
have contributed to variability in transmission. P. vivax has
been classified into two types, VK210 and VK247, based on
the differences in the Csp gene that encodes for the circum-
sporozoite protein, the major sporozoite surface protein.
Both of these strains are equally prevalent in Peru, as shown
by an equal number of pools of An. darlingi being positive for
VK210 and VK247.14 It will be of interest to investigate pos-
sible relationships of VK or other genetic types of parasite to
transmission.
The presence or absence of gametocytes and their numbers
might be considered a good predictor of mosquito infection
by malaria parasites. Our study shows that the presence of
gametocytes was higher in P. vivax transmitters than non-
transmitters (94% vs. 72%), and there was a strong correla-
tion between gametocytemia and oocysts/midgut. This obser-
vation stands in contrast to an earlier study from Thailand
that showed little relation between gametocyte density and
either oocyst number or frequency of mosquito infection in P.
vivax malaria.7 Unlike P. falciparum, the pyrogenic density of
P. vivax is significantly lower and patients present earlier for
medical care. Therefore, it may be possible that the peak
gametocyte levels have not yet been achieved and there may
be a relationship between the duration of symptoms and ga-
metocytemia. Patients presenting later in the course of the
disease may be contributing more to the continued transmis-
sion of P. vivax.
Gametocytemia as determined by real-time reverse tran-
scriptase PCR correlated well with smear results. However,
microscopic smear examination is quite variable and depen-
dent on operator experience, so one might presume that real-
time reverse transcriptase PCR might be more precise in mea-
suring gametocytemia. Nonetheless, there was no correlation
between molecular quantification of gametocytes and trans-
mission of infection to mosquitoes, as determined by number
of oocysts/midgut. Possible explanations for this might be (1)
maturity of gametocytes (i.e., P. vivax gametocyte maturity
FIGURE 5. Association of log10 real-time PCR-determined Pvs25
copy number and proportion of An. darlingi that were successfully
infected with at least one oocyst; R2  0.21, P  0.004.
FIGURE 4. Association of log10 gametocytemia and log10 oocysts
per midgut of An. darlingi infected by membrane feeding assay with
ex-vivo, human-derived P. vivax; R2  0.29, P < 0.001, N  50.
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might be heterogeneous, which would give a variable number
of Pvs25 mRNAs per cell), (2) gametocyte sex ratio that
might vary between strains, and (3) host response mecha-
nisms that could alter gametocyte infectivity, such as anti-
gametocyte antibodies, anemia, cytokines, nitric oxide, and
chitotriosidase levels. Pro-inflammatory cytokines (TNF-,
IL-1, and IL-6) and nitric oxide might influence the transmis-
sion of infection to mosquitoes by affecting gametocyte levels
or their patency. At physiologic concentrations, recombinant
TNF- is anti-parasitic, synergizing with IFN- to induce pro-
duction of nitric oxide and other toxic radicals.28 In the mouse
model, C57BL/6 IFN-−/− mice infected with P. chabaudi AS
produce lower amounts of other pro-inflammatory mediators,
including TNF- and NO, with significantly higher parasit-
emia and mortality in comparison with wild-type controls.29
Nitric oxide has been shown to be cytostatic as well as cyto-
toxic to P. falciparum, P. berghei, and P. chabaudi in vitro.30
The infectivity of gametocytes, as shown by direct feeding of
Anopheles stephensi mosquitoes on mice infected with P.
vinckei petteri, has also been experimentally observed to be
reduced during periods of schizogony that was reversed by
injecting the L-arginine analogue, N-nitro-L-arginine
(NwNLA), showing that the altered infectivity was due to
reactive nitrogen intermediates (RNI).31 Although our study
did not measure cytokine or NO levels, transmitters had
lower temperature (although not statistically significant) and
had significantly lower pulse rates, possible indicators of
lower inflammatory mediators (IL-1, TNF-), resulting in less
damage to gametocytes with resulting higher level of trans-
mission. Further studies are required to confirm this obser-
vation and determine the mechanistic relationship of pro-
inflammatory mediators and parasite transmission.
The membrane feeding method to test transmissibility of
parasites from humans to mosquitoes has been widely used
with blood collected from both P. falciparum and P. vivax
infected patients.32–37 When compared with direct feeds,
membrane feeds have been found in Thailand to result in
significantly fewer membrane feeds being infectious (53% vs.
73%). In one study, fewer mosquitoes were infected (50% vs.
57%) and fewer oocysts were produced per mosquito (8.8 vs.
13.4).24 Possible explanations for this difference are the arti-
ficial environment for mosquito feeding, effect of tempera-
ture change on gametocyte viability, the effect of handling
blood on infectivity, and the use of colonized (used in Thai-
land) versus outbred mosquitoes (used in the present study).
In situations where both experimental and control groups
have used the membrane feeding method, this difference in
transmission did not affect the final results. We used the
membrane feeding method because it is preferred by volun-
teers and by international institutional review boards, and it
has the additional advantage of allowing for experimental
manipulation of patient blood. Importantly, we have shown
here that P. vivax infection can be successfully transmitted to
an outbred group of An. darlingi mosquitoes. Most important,
even in an area of low malaria transmission intensity, there
appears to be a high level of transmission-blocking activity.
Transmission-blocking vaccines (TBV) work by inducing
antibodies against the sexual stages (gamete, zygote, and
ookinete) of the parasite that, when ingested along with a
blood meal, block parasite development in the mosquito. Un-
like vaccines against pre-erythrocytic and erythrocytic stages,
TBVs will not prevent disease but are designed to reduce
malaria transmission. Pvs25, expressed on the ookinete sur-
face, is one such vaccine candidate that is undergoing clinical
trial.38 A major emphasis in ongoing studies of transmission-
blocking vaccines is to identify a developmentally regulated
protein that induces transmission-blocking antibodies
boosted by natural infection.
Measuring human infectivity and elucidating factors affect-
ing it is the first step toward identifying potential transmis-
sion-blocking interventions that will complement currently
available means. Knowing baseline transmission patterns of
human-derived parasite infectivity for natural vectors in the
field setting will provide the basis for determining the efficacy
of transmission-blocking vaccines.
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